Inventor

Lloyd J. Old

Inventor

New York, NY, US

Overview

1985–2019

Patent span

Chemistry

Primary field (CPC C)

Patents· 136 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides32%

A61KPreparations for medical, dental or toiletry purposes21%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations14%

G01NInvestigating or analysing materials by determining their chemical or physical properties13%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests10%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms4%

C12NMicroorganisms or enzymes3%

C07HSugars2%

C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture1%

Y10TTechnical subjects covered by former us classification1%

PatentTitleYear

10,385,138Antibodies directed to membrane transporter NaP12b (SLC34A2) and uses thereof in cancer therapy2019 9,701,755'Membrane transporter NaPi2b (SCL34A2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy'2017 9,562,102'Specific binding proteins and uses thereof'2017 9,283,276'Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof'2016 9,260,524'Specific binding proteins and uses thereof'2016 9,045,533'Membrane transporter NaPi2b (SCL34A2) epitope antibodies'2015 8,652,473'Antibodies to EGF receptor epitope peptides and uses thereof'2014 8,603,474'Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy'2013 8,541,202'Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein'2013 8,440,807'A34 and A33-like 3 DNA protein, antibodies thereto and methods of treatment using same'2013 8,357,373'Methods for stimulating an immune response using bacterial antigen delivery system'2013 8,252,903'Human sarcoma-associated antigens'2012 8,142,786'Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein'2012 8,071,717'Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof'2011 7,888,100'Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein'2011 7,803,382'Method for inducing immune response to NY-CO-58'2010 7,795,409'Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per SE, and uses thereof'2010 7,767,792'Antibodies to EGF receptor epitope peptides'2010 7,662,917'Human sarcoma-associated antigens'2010 7,622,568'Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof'2009 7,589,180'Specific binding proteins and uses thereof'2009 7,560,537'Human sarcoma-associated antigens'2009 7,521,543'A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same'2009 7,354,992'Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof'2008 7,335,467'Breast cancer antigens'2008 7,314,721'Small cell lung cancer associated antigens and uses therefor'2008 7,291,335'Isolated nucleic acid molecules encoding ESO-1 peptides and uses thereof'2007 7,259,235'Method for generating an immune response and reagents therefor'2007 7,132,507'Isolated cancer associated antigens NY-MEL 1 and NY-MEL 3, peptides based thereon, and their uses'2006 7,115,729'Isolated nucleic acid molecules which encode peptides which bind to MHC class II molecules, such as HLA-DR53'2006 7,009,035'Isolated peptides which bind to HLA-C molecules and uses thereof'2006 6,982,316'Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer'2006 6,911,529'Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof'2005 6,846,910'Isolated proteins containing portions of FAPÎ± and other proteins'2005 6,830,924'Isolated nucleic acid molecule encoding cancer associated antigens, the antigens per se, and uses thereof'2004 6,794,501'Colon cancer antigen panel'2004 6,774,226'Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof'2004 6,723,832'Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof'2004 6,686,147'Cancer associated antigens and uses therefor'2004 6,652,853'Method for treating cancer using A33 specific antibodies and chemotherapeutic agents'2003 6,576,756'Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof'2003 6,525,177'Truncated forms of NY-ESO-1 protein'2003 6,518,415'Recombinant human anti-Lewis Y antibodies'2003 6,517,837'Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer'2003 6,506,875'Isolated peptides which bind to HLA-C molecules and uses thereof'2003 6,448,073'Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof'2002 6,440,663'Renal cancer associated antigens and uses therefor'2002 6,428,969'Method for determining oncogenic activity of a substance'2002 6,403,373'Isolated nucleic acid molecules associated with colon, renal, and stomach cancer and methods of using these'2002 6,391,302'Method for treating cancers which present antigen FB5 with humanized antibodies'2002 6,355,256'Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof'2002 6,348,195'Method for treating cancers'2002 6,346,249'Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products'2002 6,342,587'A33 antigen specific immunoglobulin products and uses thereof'2002 6,339,140'SSX family proteins'2002 6,338,947'Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith'2002 6,310,185'Recombinant human anti-Lewis Y antibodies'2001 6,297,364'Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof'2001 6,291,235'Isolated nucleic acid which encodes protein which binds to A33 antibody'2001 6,291,658'Isolated nucleic acid molecules encoding SSX family members and thereof'2001 6,287,756'Methods for determining presence of cancer in a sample by determining expression of an SSX gene'2001 6,274,145'Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof'2001 6,255,470'Isolated nucleic acid molecule encoding an esophageal cancer associated antigen'2001 6,251,603'Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample'2001 6,252,052'Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies'2001 6,217,868'Methods for detecting cancer cells by using humanized antibodies which bind specifically to FB5 antigen'2001 6,190,640'Method for treating neoplasia using humanized antibodies which bind to antigen A33'2001 6,140,050'Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith'2000 6,124,106'Method for detecting cancers'2000 6,090,930'Recombinant human anti-FB5 antibodies'2000 6,069,233'Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof'2000 6,063,359'Method for determining oncogenic activity of a substance'2000 6,057,115'Process for producing GM2 specific antibodies'2000 6,043,084'Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer'2000 6,025,481'Isolated nucleic acid molecules which encode human anti-Lewis b antibodies'2000 5,977,329'Methods of synthesizing GM3'1999 5,965,373'Isolated dimeric fibroblast activation protein .alpha., and uses thereof'1999 5,958,412'Methods of treating colon cancer utilizing tumor-specific antibodies'1999 5,952,484'Recombinant human anti-LK26 antibodies'1999 5,874,060'Recombinant human anti-Lewis Y antibodies'1999 5,854,007'Process for producing GM1 specific antibodies'1998 5,851,526'Methods of treating colon cancer utilizing tumor-specific antibodies'1998 5,843,448'Tumor rejection antigen precursor'1998 5,811,522'Recombinant humanized anti-FB5 antibodies'1998 5,804,381'Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof'1998 5,795,961'Recombinant human anti-Lewis b antibodies'1998 5,767,242'Isolated dimeric fibroblast activation protein alpha, and uses thereof'1998 5,756,695'Methods of synthesizing GM2'1998 5,712,369'Isolated protein which binds to A33 antibody, and peptides corresponding to portions of the protein'1998 5,674,749'Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof'1997 5,646,253'Recombinant human anti-LK26 antibodies'1997 5,643,550'Method of treating colorectal carcinoma lesion and composition for use therein'1997 5,618,534'Isolated antigen endo glyx-1'1997 5,587,299'Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof'1996 5,565,356'Hybridoma cell lines which produce monoclonal antibodies having the properties of monoclonal antibody 100-310 and the monoclonal antibodies produced by these hybridoma cell lines'1996 5,541,104'Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1'1996 5,536,641'Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1 and uses thereof for detection of, and isolation of, vascular endothelial cells'1996 5,437,865'Isolated sialylated glycoprotein endosialin, which is expressed by tumor associated vascular endothelium'1995 5,431,897'Method of imaging colorectal carcinoma lesion and composition for use therein'1995 5,342,757'Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof'1994 5,177,000'Monoclonal antibodies selective for prostate cancer and diagnostic immunoassay for prostate cancer'1993 5,173,292'Monoclonal antibodies which specifically recognize galactosyl-globoside, compositions containing same and methods of using same'1992 5,168,043'Blood group antigen panel'1992 5,160,723'Method of imaging colorectal carcinoma lesion and composition for use therein'1992 5,143,843'Method for production of monoclonal antibodies for cancer diagnosis and therapy'1992 5,104,652'Compositions and method for treatment of cancer using monoclonal antibody against G.sub.D3 ganglioside together with IL-2'1992 5,102,663'Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3'1992 5,059,523'Cell-surface glycoproteins of human sarcomas'1991 5,023,320'Process for the purification of physiologically active substance having antitumor activity'1991 5,009,995'Monoclonal antibodies to melanoma cells'1991 5,006,470'Human monoclonal antibodies to cell surface antigens of melanoma'1991 4,970,299'Monoclonal antibodies selective for prostate cancer'1990 4,935,344'Method for characterizing types of renal carcinoma and prognosis'1990 4,870,163'Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor'1989 4,865,998'Monoclonal antibodies to human lung cancers and method'1989 4,863,854'Monoclonal antibodies to mucin-like human differentiation antigens'1989 4,851,332'Choriocarcinoma monoclonal antibodies and antibody panels'1989 4,808,704'Monoclonal antibodies to cell surface antigens of human malignant melanoma'1989 4,806,628'Monoclonal antibodies against melanocytes'1989 4,798,790'Monoclonal antibody specific for a pigmentation associated antigen'1989 4,770,995'Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin'1988 4,762,800'Monoclonal antibodies to cell surface antigens of human teratocarcinomas'1988 4,727,021'Human monoclonal antibodies to cytokeratin'1988 4,713,352'Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma'1987 4,695,538'Human monoclonal antibodies to cell surface antigens'1987 4,693,966'Human monoclonal antibodies from lymphocytes of patients with malignant melanoma'1987 4,678,747'Monoclonal antibodies for detection of an H (O) blood group antigen'1987 4,666,845'Monoclonal antibodies to ovarian, cervical and uterine human cancers and method of diagnosis'1987 4,650,756'Monoclonal antibodies to cell surface antigens of human renal cancer'1987 4,643,971'Monoclonal antibodies to human bladder and ureter cancers and method'1987 4,642,291'Cell surface antigens of human astrocytoma'1987 4,613,576'Human monoclonal antibodies to cancer cells'1986 4,591,572'Pigmentation associated, differentiation antigen of human melanoma and autologous antibody'1986 4,579,827'Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies'1986 4,562,160'Melanoma tumor antigen and autologous antibody'1985 4,507,391'Method for detecting the presence of G.sub.D3 ganglioside'1985

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1985–2013Patents assigned to SLOAN KETTERING INST CANCER (69)· patent assignee history

1985–2019Based in New York, NY, US· patent location history

1994–2017Patents assigned to LUDWIG INST CANCER RES (71)· patent assignee history

1996–2011Patents assigned to CORNELL RES FOUNDATION INC (19)· patent assignee history

2009Based in NY, NY, US· patent location history

2010–2019Patents assigned to LUDWIG INST FOR CANCER RES LTD (8)· patent assignee history

2012–2016Patents assigned to OLD LLOYD J (7)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
LUDWIG INST CANCER RES	71	1994–2017
SLOAN KETTERING INST CANCER	69	1985–2013
CORNELL RES FOUNDATION INC	19	1996–2011
LUDWIG INST FOR CANCER RES LTD	8	2010–2019
OLD LLOYD Jself	7	2012–2016

Locations

Location	Patents	Span
New York, New York, US	135	1985–2019
NY, New York, US	1	2009